Show simple item record

dc.contributor.authorBulage, Lilian
dc.contributor.authorSsewanyana, Isaac
dc.contributor.authorNankabirwa, Victoria
dc.contributor.authorNsubuga, Fred
dc.contributor.authorKihembo, Christine
dc.contributor.authorPande, Gerald
dc.contributor.authorArio, Alex R.
dc.contributor.authorMatovu, Joseph K. B.
dc.contributor.authorWanyenze, Rhoda K.
dc.contributor.authorKiyaga, Charles
dc.date.accessioned2021-12-11T10:54:58Z
dc.date.available2021-12-11T10:54:58Z
dc.date.issued2017
dc.identifier.citationBulage, L., Ssewanyana, I., Nankabirwa, V., Nsubuga, F., Kihembo, C., Pande, G., ... & Kiyaga, C. (2017). Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014 – July 2015. BMC infectious diseases , 17 (1), 1-11. DOI 10.1186/s12879-017-2428-3en_US
dc.identifier.other10.1186/s12879-017-2428-3
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/305
dc.description.abstractDespite the growing number of people on antiretroviral therapy (ART), there is limited information about virological non suppression and its determinants among HIV-positive (HIV+) individuals enrolled in HIV care in many resource-limited settings. We estimated the proportion of virologically non-suppressed patients, and identified the factors associated with virological non suppression. Methods: We conducted a descriptive cross-sectional study using routinely collected program data from viral load (VL) samples collected across the country for testing at the Central Public Health Laboratories (CPHL) in Uganda. Data were generated between August 2014 and July 2015. We extracted data on socio-demographic, clinical and VL testing results. We defined virological non-suppression as having ≥1000 copies of viral RNA/ml of blood for plasma or ≥5000 copies of viral RNA/ml of blood for dry blood spots. We used logistic regression to identify factors associated with virological non-suppression. Results: The study was composed of 100,678 patients; of these, 94,766(94%) were for routine monitoring, 3492(4%) were suspected treatment failures while 1436(1%) were repeat testers after suspected failure. The overall proportion of non suppression was 11%. Patients on routine monitoring registered the lowest (10%) proportion of nonsuppressed patients. Virological non-suppression was higher among suspected treatment failures (29%) and repeat testers after suspected failure (50%). Repeat testers after suspected failure were six times more likely to have virological non-suppression (ORadj = 6.3, 95%CI = 5.5–7.2) when compared with suspected treatment failures (ORadj = 3.3, 95%CI = 3.0–3.6). The odds of virological non-suppression decreased with increasing age, with children aged 0–4 years (ORadj = 5.3, 95%CI = 4.6–6.1) and young adolescents (ORadj = 4.1, 95%CI = 3.7–4.6) registering the highest odds. Poor adherence (ORadj = 3.4, 95%CI = 2.9–3.9) and having active TB (ORadj = 1.9, 95%CI = 1.6–2.4) increased the odds of virological non-suppression. However, being on second/third line regimens (ORadj = 0.86, 95%CI = 0.78–0.95) protected patients against virological non-suppression. Conclusion: Young age, poor adherence and having active TB increased the odds of virological non-suppression while second/third line ART regimens were protective against non-suppression. We recommend close follow up and intensified targeted adherence support for repeat testers after suspected failure, children and adolescents.en_US
dc.language.isoenen_US
dc.publisherBMC infectious diseasesen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectVirological non-suppressionen_US
dc.subjectUgandaen_US
dc.titleFactors Associated with Virological Nonsuppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record